# A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Source: https://onco.cc/trials/nct07063745/  
OnCo record `nct07063745` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Navlimetostat in non-small-cell lung cancer, now recruiting.

## Summary

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion is a phase 2/3 interventional study registered as NCT07063745, led by Bristol-Myers Squibb, and recruiting on the registry. Official title: A Randomised Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion. Planned enrolment is 590 participants (estimated). The study started in 2026-01-02 and primary completion is expected in 2031-08-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: MountainTAP-29
- Tags: ctgov-ingest
- Registry id: NCT07063745
- Phase: 2/3
- Setting: A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Sponsor: Bristol-Myers Squibb
- Enrolled: 590

## Sources

- ClinicalTrials.gov NCT07063745: https://clinicaltrials.gov/study/NCT07063745

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Navlimetostat](https://onco.cc/drugs/navlimetostat/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07063745.json